Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 77,862
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12618065 | MiRNA detargeting system for tissue specific interference | 🖼🧊📄§ | 2026-05-05 | 2038-10-02 | 0 | 31 |
| 12618066 | Promoter having high activity in activated T-cell | 🖼🧊📄§ | 2026-05-05 | 2040-11-13 | 0 | 31 |
| 12618076 | Methods of engineering platelets for targeting circulating tumor cells | 🖼🧊📄§ | 2026-05-05 | 2040-09-30 | 0 | 31 |
| 12618082 | Engineered muscle targeting compositions | 🖼🧊📄§ | 2026-05-05 | 2042-03-29 | 0 | 31 |
| 12617762 | Carboxy derivatives with antiinflamatory properties | 🖼🧊📄§ | 2026-05-05 | 2040-12-23 | 0 | 31 |
| 12617790 | Mitragynine analogs and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2041-06-24 | 0 | 31 |
| 12617805 | Codrug that disintegrates in intestine, preparation therefor, and use thereof | 🖼🧊📄§ | 2026-05-05 | 2041-07-19 | 0 | 31 |
| 12617812 | Platinum(IV) complexes, methods of manufacture, compositions containing, and methods of use thereof | 🖼🧊📄§ | 2026-05-05 | 2042-05-25 | 0 | 31 |
| 12617807 | Long lasting opioid reversal using hydrogen peroxide-induced release in blood | 🖼🧊📄§ | 2026-05-05 | 2042-04-01 | 0 | 31 |
| 12617822 | Arc-based capsids and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2042-10-13 | 0 | 31 |
| 12617820 | Engineered coronavirus spike (s) protein and methods of use thereof | 🖼🧊📄§ | 2026-05-05 | 2041-05-28 | 0 | 31 |
| 12617828 | Genetically modified immune cell, preparation method therefor, and application | 🖼🧊📄§ | 2026-05-05 | 2040-05-06 | 0 | 31 |
| 12617826 | CLEC2 fusion protein and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2041-09-29 | 0 | 31 |
| 12617831 | Peptide targeting GIP and GLP-2 receptors for treating bone disorders | 🖼🧊📄§ | 2026-05-05 | 2040-02-21 | 0 | 31 |
| 12617833 | Tethered interleukin-15 and interleukin-21 | 🖼🧊📄§ | 2026-05-05 | 2039-02-07 | 0 | 31 |
| 12617832 | Genetic engineering of B cell receptors and uses thereof in antigen-induced antibody secretion | 🖼🧊📄§ | 2026-05-05 | 2041-03-12 | 0 | 31 |
| 12617836 | Tumor environment specific expression of effector genes | 🖼🧊📄§ | 2026-05-05 | 2042-03-21 | 0 | 31 |
| 12617837 | Composition for use in treatment of allergic diseases | 🖼🧊📄§ | 2026-05-05 | 2040-02-28 | 0 | 31 |
| 12617839 | Factor VIII chimeric proteins and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2041-11-05 | 0 | 31 |
| 12617841 | Nucleic acid antibody constructs for use against respiratory syncytial virus | 🖼🧊📄§ | 2026-05-05 | 2039-01-31 | 0 | 31 |
| 12617850 | Treatment of PD-L1-positive melanoma using an anti-PD-1 antibody | 🖼🧊📄§ | 2026-05-05 | 2042-03-22 | 0 | 31 |
| 12617849 | Antigen specific CD19-targeted CAR-T cells | 🖼🧊📄§ | 2026-05-05 | 2040-04-29 | 0 | 31 |
| 12617856 | Protease-cleavable substrates and methods of use thereof | 🖼🧊📄§ | 2026-05-05 | 2045-03-17 | 0 | 31 |
| 12617867 | Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof | 🖼🧊📄§ | 2026-05-05 | 2039-09-25 | 0 | 31 |
| 12617870 | Methods of reversing ticagrelor activity | 🖼🧊📄§ | 2026-05-05 | 2039-09-20 | 0 | 31 |
| 12617864 | Methods of activating and proliferating exhausted CD8 T cells, CD8 T cells with enhanced activity prepared by the same, and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2042-04-12 | 0 | 31 |
| 12617866 | Humanized antibodies to mucin-16 and methods of use thereof | 🖼🧊📄§ | 2026-05-05 | 2040-05-07 | 0 | 31 |
| 12618031 | Delivery devices | 🖼🧊📄§ | 2026-05-05 | 2041-06-24 | 0 | 31 |
| 12616823 | Sustained release formulations in delivery devices | 🖼🧊📄§ | 2026-05-05 | 2039-09-10 | 0 | 31 |
| 12616761 | CXCR4-targeting compounds | 🖼🧊📄§ | 2026-05-05 | 2044-06-27 | 0 | 31 |
| 12616760 | Synthetic cyclic peptide mimetics | 🖼🧊📄§ | 2026-05-05 | 2041-09-13 | 0 | 31 |
| 12616684 | Pulmonary fibrosis medicine containing pyrazole derivative | 🖼🧊📄§ | 2026-05-05 | 2041-03-23 | 0 | 31 |
| 12616705 | Use of cannabinoids in the treatment of Angelman syndrome | 🖼🧊📄§ | 2026-05-05 | 2043-05-02 | 0 | 31 |
| 12616706 | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations | 🖼🧊📄§ | 2026-05-05 | 2040-03-06 | 0 | 31 |
| 12616759 | Uses of labeled HSP90 inhibitors | 🖼🧊📄§ | 2026-05-05 | 2043-01-31 | 0 | 31 |
| 12616741 | Therapeutic combination comprising a pulmonary surfactant and a steroid for the prophylaxis of BPD | 🖼🧊📄§ | 2026-05-05 | 2041-03-17 | 0 | 31 |
| RE050880 | Anti-human OX40L antibodies and methods of treatment | 🖼🧊📄§ | 2026-05-05 | 2042-08-01 | 0 | 31 |
| 12616683 | Combination therapy for the treatment of gastrointestinal stromal tumors | 🖼🧊📄§ | 2026-05-05 | 2044-04-10 | 0 | 31 |
| 12616756 | Dimeric antibodies | 🖼🧊📄§ | 2026-05-05 | 2044-08-16 | 0 | 31 |
| 12616704 | Cannabichromene formulation for pain management | 🖼🧊📄§ | 2026-05-05 | 2041-03-31 | 0 | 31 |
| 12616757 | Compositions and methods for correction of heritable ocular disease | 🖼🧊📄§ | 2026-05-05 | 2041-04-14 | 0 | 31 |
| 12617835 | Chimeric autoantibody receptor (CAAR) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease | 🖼🧊📄§ | 2026-05-05 | 2040-06-05 | 0 | 31 |
| 12616681 | Compositions and methods for treating renal injury | 🖼🧊📄§ | 2026-05-05 | 2042-08-22 | 0 | 31 |
| 12616677 | Injectable pharmaceutical compositions and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2040-05-01 | 0 | 31 |
| 12616678 | Methods to of aldehyde dehydrogenases for treatment of cancer | 🖼🧊📄§ | 2026-05-05 | 2041-06-10 | 0 | 31 |
| 12616689 | Regimens of tafenoquine for prevention of malaria in malaria-naive subjects | 🖼🧊📄§ | 2026-05-05 | 2043-08-30 | 0 | 31 |
| 12616690 | Specific AKT3 activator and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2044-03-15 | 0 | 31 |
| 12616687 | Treatment of viral infection, disease or disorder using a selective sir agonist | 🖼🧊📄§ | 2026-05-05 | 2042-11-04 | 0 | 31 |
| 12616694 | Pharmaceutical compositions for subcutaneous administration of levosimendan | 🖼🧊📄§ | 2026-05-05 | 2041-12-08 | 0 | 31 |
| 12616700 | Therapeutic regimen | 🖼🧊📄§ | 2026-05-05 | 2043-07-07 | 0 | 31 |